Broadcast Date: 
  • Time: 

Due to its extreme potential to revolutionize the biopharma industry, the benefits of mRNA as a novel therapeutic are well known. However, the path leading to the development of mRNA medicines can be challenging and is often less discussed. Qualities like nucleic acid stability, immunogenicity, and delivery of the final product are all critical factors that face mRNA medicines and need to be addressed more frequently. Thankfully, novel methodologies and techniques to assist drug developers are on the rise and have the potential to streamline production workflows and increase production and efficiency.

This is the second webinar in a series of four, cohosted by GEN and The CRISPR Journal, that is diving deep into the burgeoning world of mRNA research and therapeutics. Our distinguished guest for this event, Dr. Edward Miracco, will take us through his extensive experience with mRNA chemistry, sequence design, and commercial-scale production. Dr. Miracco has faced many challenges in his work and will tell us about several vital considerations that could significantly aid your mRNA research endeavors.

 

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.

Edward Miracco
Edward Miracco, PhD
Director, RNA Chemical Biology/External Technology Investments
Moderna, Inc.

TriLink Biotechnologies logo